Homologous prime-boost vaccination with OVA entrapped in self-adjuvanting archaeosomes induces high numbers of OVA-Specific CD8+ T cells that protect against subcutaneous B16-OVA melanoma

Download
  1. (PDF, 730 KB)
  2. Get@NRC: Homologous prime-boost vaccination with OVA entrapped in self-adjuvanting archaeosomes induces high numbers of OVA-Specific CD8+ T cells that protect against subcutaneous B16-OVA melanoma (Opens in a new window)
DOIResolve DOI: http://doi.org/10.3390/vaccines4040044
AuthorSearch for: ; Search for: ; Search for:
TypeArticle
Journal titleVaccines
ISSN2076-393X
Volume4
Issue4
Pages44
SubjectCD8 T cell response; archaeosome; prime-boost; B16; liposome; tumor vaccine; central memory; effector memory
AbstractHomologous prime-boost vaccinations with live vectors typically fail to induce repeated strong CD8+ T cell responses due to the induction of anti-vector immunity, highlighting the need for alternative delivery vehicles. The unique ether lipids of archaea may be constituted into liposomes, archaeosomes, which do not induce anti-carrier responses, making them an ideal candidate for use in repeat vaccination systems. Herein, we evaluated in mice the maximum threshold of antigen-specific CD8+ T cell responses that may be induced by multiple homologous immunizations with ovalbumin (OVA) entrapped in archaeosomes derived from the ether glycerolipids of the archaeon Methanobrevibacter smithii (MS-OVA). Up to three immunizations with MS-OVA administered in optimized intervals (to allow for sufficient resting of the primed cells prior to boosting), induced a potent anti-OVA CD8+ T cell response of up to 45% of all circulating CD8+ T cells. Additional MS-OVA injections did not add any further benefit in increasing the memory of CD8+ T cell frequency. In contrast, OVA expressed by Listeria monocytogenes (LM-OVA), an intracellular bacterial vector failed to evoke a boosting effect after the second injection, resulting in significantly reduced antigen-specific CD8+ T cell frequencies. Furthermore, repeated vaccination with MS-OVA skewed the response increasingly towards an effector memory (CD62low) phenotype. Vaccinated animals were challenged with B16-OVA at late time points after vaccination (+7 months) and were afforded protection compared to control. Therefore, archaeosomes constituted a robust particulate delivery system to unravel the kinetics of CD8+ T cell response induction and memory maintenance and constitute an efficient vaccination regimen optimized for tumor protection.
Publication date
LanguageEnglish
AffiliationHuman Health Therapeutics; National Research Council Canada
Peer reviewedYes
NPARC number23001165
Export citationExport as RIS
Report a correctionReport a correction
Record identifier47ccb66d-22f3-4b57-af88-ccd491e36d86
Record created2016-12-21
Record modified2016-12-21
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)